Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors

Trial Profile

Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Daratumumab (Primary) ; Nivolumab (Primary)
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 17 Oct 2020 to 23 Oct 2020.
    • 10 Jul 2017 Planned primary completion date changed from 9 Jun 2019 to 16 Jun 2019.
    • 10 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top